Eastgate Biotech Corp.
ETBI · OTC
12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.07 | 0.00 | 0.00 | 0.06 |
| FCF Yield | 0.42% | -3.90% | 0.00% | -3.99% |
| EV / EBITDA | -6.12 | -8.56 | -0.93 | -4.47 |
| Quality | ||||
| ROIC | 63.23% | 35.64% | 132.33% | 89.52% |
| Gross Margin | -110.37% | -50.60% | -1.93% | 0.00% |
| Cash Conversion Ratio | -0.03 | 0.17 | 0.38 | 0.13 |
| Growth | ||||
| Revenue 3-Year CAGR | -14.11% | – | 6.03% | – |
| Free Cash Flow Growth | 123.31% | 82.12% | -270.62% | 31.48% |
| Safety | ||||
| Net Debt / EBITDA | -1.45 | -3.20 | -0.93 | -0.68 |
| Interest Coverage | -12.10 | -8.90 | -10.79 | -16.51 |
| Efficiency | ||||
| Inventory Turnover | 2.26 | 2.35 | 1.36 | 0.00 |
| Cash Conversion Cycle | -1,645.22 | -1,186.51 | -1,439.73 | 0.00 |